CH BIOTECH SER (08037) Reports February 2026 Monthly Return on Share Capital and Convertible Bonds

Bulletin Express03-04

China Biotech Services Holdings Limited (CH BIOTECH SER, 08037) disclosed that its authorized share capital remained unchanged at HKD 200.00 million as of February’s month-end, consisting of 2.00 billion ordinary shares at HKD 0.10 par value each. The total number of issued shares also stayed at 975.73 million, with no movements in treasury shares.

Public float requirements stood at 25%, and the issuer confirmed compliance with the relevant thresholds. Regarding convertible bonds, the company noted a USD 6.00 million issuance dated 27 December 2024, with the conversion price revised to HKD 1.11 per share, translating to a maximum of 42.43 million potential new shares. Another issuance on 20 February 2026 involved USD 35.00 million in convertible bonds at a conversion price of HKD 0.66 per share, allowing for up to 412.58 million potential new shares. No actual share conversion or issuance took place in February 2026 under these instruments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106449198?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 14:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106449198","market":"us","top_or_hot":-1,"title":"CH BIOTECH SER (08037) Reports February 2026 Monthly Return on Share Capital and Convertible Bonds","media":"Bulletin Express","content":"<p>China Biotech Services Holdings Limited (CH BIOTECH SER, 08037) disclosed that its authorized share capital remained unchanged at HKD 200.00 million as of February’s month-end, consisting of 2.00 billion ordinary shares at HKD 0.10 par value each. The total number of issued shares also stayed at 975.73 million, with no movements in treasury shares.</p>\n<p>Public float requirements stood at 25%, and the issuer confirmed compliance with the relevant thresholds. Regarding convertible bonds, the company noted a USD 6.00 million issuance dated 27 December 2024, with the conversion price revised to HKD 1.11 per share, translating to a maximum of 42.43 million potential new shares. Another issuance on 20 February 2026 involved USD 35.00 million in convertible bonds at a conversion price of HKD 0.66 per share, allowing for up to 412.58 million potential new shares. No actual share conversion or issuance took place in February 2026 under these instruments.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CH BIOTECH SER (08037) Reports February 2026 Monthly Return on Share Capital and Convertible Bonds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCH BIOTECH SER (08037) Reports February 2026 Monthly Return on Share Capital and Convertible Bonds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-04 14:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Biotech Services Holdings Limited (CH BIOTECH SER, 08037) disclosed that its authorized share capital remained unchanged at HKD 200.00 million as of February’s month-end, consisting of 2.00 billion ordinary shares at HKD 0.10 par value each. The total number of issued shares also stayed at 975.73 million, with no movements in treasury shares.</p>\n<p>Public float requirements stood at 25%, and the issuer confirmed compliance with the relevant thresholds. Regarding convertible bonds, the company noted a USD 6.00 million issuance dated 27 December 2024, with the conversion price revised to HKD 1.11 per share, translating to a maximum of 42.43 million potential new shares. Another issuance on 20 February 2026 involved USD 35.00 million in convertible bonds at a conversion price of HKD 0.66 per share, allowing for up to 412.58 million potential new shares. No actual share conversion or issuance took place in February 2026 under these instruments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08037","symbol_name":"中国生物科技服务","start_time":0,"source_url":"","article_id":"1106449198","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106449198","pubTimestamp":1772605483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Biotech Services Holdings Limited (CH BIOTECH SER, 08037) disclosed that its authorized share capital remained unchanged at HKD 200.00 million as of February’s month-end, consisting of 2.00...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08037":"中国生物科技服务"},"translate_title":"CH BIOTECH SER(08037)报告2026年02月股本及可换股债券月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08037":1},"content_text":"China Biotech Services Holdings Limited (CH BIOTECH SER, 08037) disclosed that its authorized share capital remained unchanged at HKD 200.00 million as of February’s month-end, consisting of 2.00 billion ordinary shares at HKD 0.10 par value each. The total number of issued shares also stayed at 975.73 million, with no movements in treasury shares.\nPublic float requirements stood at 25%, and the issuer confirmed compliance with the relevant thresholds. Regarding convertible bonds, the company noted a USD 6.00 million issuance dated 27 December 2024, with the conversion price revised to HKD 1.11 per share, translating to a maximum of 42.43 million potential new shares. Another issuance on 20 February 2026 involved USD 35.00 million in convertible bonds at a conversion price of HKD 0.66 per share, allowing for up to 412.58 million potential new shares. No actual share conversion or issuance took place in February 2026 under these instruments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106449198","isCrawlerRequest":true}